Alnylam Pharmaceuticals
ALNY
#692
Rank
NZ$62.08 B
Marketcap
NZ$465.04
Share price
1.94%
Change (1 day)
-13.39%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2026 (TTM): NZ$6.60

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is NZ$6.46. In 2025 the company made an earnings per share (EPS) of NZ$3.07.

EPS history for Alnylam Pharmaceuticals from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$6.60115.04%
2025NZ$3.07
2023NZ-$6.02-62%
2022NZ-$15.8429.03%
2021NZ-$12.28-3.36%
2020NZ-$12.71-8.48%
2019NZ-$13.887.67%
2018NZ-$12.8939.74%
2017NZ-$9.2312.94%
2016NZ-$8.1738.84%
2015NZ-$5.88-32.88%
2014NZ-$8.77259.44%
2013NZ-$2.44-31.25%
2012NZ-$3.55

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Novartis
NVS
NZ$11.97 85.22%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
NZ$4.37-32.46%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
NZ$72.53 1,022.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
NZ-$14.19-319.53%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
NZ-$1.25-119.26%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
NZ-$0.41-106.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
NZ$2.34-63.85%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
NZ$0.60-90.77%๐Ÿ‡บ๐Ÿ‡ธ USA